VP-301 is under clinical development by Virtuoso Therapeutics and currently in Phase I for Relapsed Multiple Myeloma. According to GlobalData, Phase I drugs for Relapsed Multiple Myeloma have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how VP-301’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Virtuoso Therapeutics overview
Virtuoso Therapeutics specializes in developing the therapies for the cancer treatment. Virtuoso Therapeutics is headquartered in San Mateo, California, the US.
For a complete picture of VP-301’s drug-specific PTSR and LoA scores, buy the report here.